EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

Roisin M McAvera iD, Izabela Cymer, John Quinn, Phillip T Murphy iD, Patrick Thornton, Niamh McAuley, Harmony Black, Omar Abdelzaher iD, Catherine Duane, Tatiana Cichocka, Eva Szegezdi, Meegahage Perera und 13 weitere

European Journal of Haematology · 2026-12 · 117 (6) · 1518-1530

DOI: 10.1111/ejh.70282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 07.08.2026. Verfasst von Roisin M McAvera und 24 weiteren Autor:innen. Beteiligte Einrichtung: Multiple Myeloma Research Group, Royal College of Surgeons in Ireland, Dublin, Ireland. Hauptthemen laut MEDLINE: Multiple Myeloma, Biomarkers, Tumor, Transcriptome. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: SkylineDx, Janssen Biotech, Celgene.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.

Methods

Baseline genomic risk was assessed using the MMprofiler microarray in 114 TE‐NDMM patients. MRD was evaluated 100 days after autologous stem cell transplantation using next‐generation sequencing at the International Myeloma Working Group‐recommended sensitivity of 10 −5 . Differential gene expression and copy number analyses were performed and compared with digital MLPA and retrospective fluorescence in situ hybridisation (FISH).

Results

SKY92 classified 25.4% (29/114) of patients as high‐risk and was associated with inferior progression‐free survival and other adverse disease features. MRD assessment achieved 10 −5 sensitivity, although MRD negativity was not associated with SKY92 risk status. High‐risk disease demonstrated enrichment of pathways involved in chromosomal stability and DNA repair. NUF2 emerged as a key independent prognostic marker, showing strong association with high‐risk biology and identifying a potential molecular driver of aggressive disease. Copy number abnormality detection showed high concordance between MMprofiler, digital MLPA, and retrospective FISH.

Conclusions

This first characterisation of SKY92‐defined high‐risk multiple myeloma in Ireland supports integrated genomic profiling for clinical risk stratification and identifies NUF2 as a promising candidate driver, demonstrating that deep profiling of high‐risk disease may help to discover new targets for this challenging entity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaBiomarkers, TumorTranscriptomeHumansPrognosisGene Expression ProfilingNeoplasm, ResidualIn Situ Hybridization, FluorescenceDNA Copy Number VariationsMaleFemaleProgression-Free Survival

Stichwörter der Autor:innen

MRDNUF2SKY92gene expression profilinghigh‐risk

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Multiple Myeloma Research Group, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Molecular Pathology Laboratory, Royal College of Surgeons in Ireland, Dublin, Ireland.
  • Department of Haematology, Beaumont RCSI Cancer Centre, Dublin, Ireland.
  • Blood Cancer Network Ireland, University of Galway, Galway, Ireland.
  • School of Biological and Chemical Sciences, University of Galway, Galway, Ireland.
  • Department of Haematology, Midland Regional Hospital Tullamore, Tullamore, Ireland.

ORCID-Profile: Roisin M McAvera, Phillip T Murphy, Omar Abdelzaher, Janusz Krawczyk, Ezzat Elhassadi, Michael O'Dwyer

Förderung

  • SkylineDx
  • Janssen Biotech
  • Celgene
  • Amgen
  • Haematology Association of Ireland
  • Irish Cancer Society
  • Johnson & Johnson Innovative Medicine
  • Amgen Foundation

Zitieren

APA

McAvera, R. M., Cymer, I., Quinn, J., Murphy, P. T., Thornton, P., McAuley, N., Black, H., Abdelzaher, O., Duane, C., Cichocka, T., Szegezdi, E., Perera, M., Crotty, G. M., Connolly, M., Walsh, A., Clifford, R., Krawczyk, J., Meenaghan, T., Mykytiv, V., …, & Glavey, S. V. (2026). SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver. European Journal of Haematology, 117(6), 1518-1530. https://doi.org/10.1111/ejh.70282

Vancouver

McAvera RM, Cymer I, Quinn J, Murphy PT, Thornton P, McAuley N, et al. SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver. European Journal of Haematology. 2026;117(6):1518-1530. doi:10.1111/ejh.70282

BibTeX
@article{McAvera2026,
  author = {McAvera, Roisin M and Cymer, Izabela and Quinn, John and Murphy, Phillip T and Thornton, Patrick and McAuley, Niamh and Black, Harmony and Abdelzaher, Omar and Duane, Catherine and Cichocka, Tatiana and Szegezdi, Eva and Perera, Meegahage and Crotty, Gerard M and Connolly, Michelle and Walsh, Aileen and Clifford, Ruth and Krawczyk, Janusz and Meenaghan, Teresa and Mykytiv, Vitaliy and Elhassadi, Ezzat and Coyne, Mark and Cummins, Robert J and Kuiper, Rowan and O'Dwyer, Michael and Glavey, Siobhan V},
  title = {SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {117},
  number = {6},
  pages = {1518--1530},
  doi = {10.1111/ejh.70282}
}
Kostenlos starten →